Opdivo: Growth Trajectory in Lung Cancer Indication
Bristol-Myers Squibb’s (BMY) Opdivo reported total revenues of $1.79 billion in the third quarter, which is a rise of 42% YoY (year-over-year). Among the revenues, the company earned $1.14 billion from the sale of Opdivo in the US market, which is a rise of 47% YoY.